MedTrace Logo

Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma

NCT07622940 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-06-03

No results posted yet for this study

Summary

This example study evaluates the safety, feasibility, cellular kinetics, and preliminary anti-tumor activity of EBNK-1822H2, an illustrative allogeneic cord blood-derived dual-target CAR-NK cell product directed against CLDN18.2 and HER2, in adults with relapsed/refractory or metastatic esophageal adenocarcinoma after standard therapy. The study uses dose escalation followed by biomarker-defined expansion and prospectively records EGFR expression as an exploratory biomarker of antigen escape.

Conditions

  • Recurrent or Metastatic Esophageal Adenocarcinoma
  • Biomarker-selected CLDN18.2-positive and/or HER2-positive Disease

Interventions

BIOLOGICAL

EBNK-1822H2 dual-target CLDN18.2/HER2 CAR-NK cells

Illustrative allogeneic cord blood-derived NK-cell product engineered to recognize CLDN18.2 and HER2.

DRUG

Fludarabine

Lymphodepletion backbone

DRUG

Cyclophosphamide

Lymphodepletion backbone

Sponsors & Collaborators

  • Beijing Biotech

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-02
Primary Completion
2027-03-14
Completion
2028-03-17

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07622940 on ClinicalTrials.gov